28978 Federal Register / Vol. 72, No. 99 / Wednesday, May 23, 2007 / Notices 

3. Approve and disapprove contract 

proposals for award, not including 

proposals for national interim grantee 

contracts. 

4. Approve and disapprove quality 

improvement plans (QIP) as required 

under 42 U.S.C. 9836A(d)(2)(B). 

5. Conduct, as the responsible HHS 

official, informal meetings with current 

grantees or current or prospective 

delegate agencies as authorized by 45 

CFR part 1303.11 and 1303.12. 

6. Conduct, as the responsible HHS 

official, informal meetings authorized 

by 45 CFR part 1303.21 related to 

appeals by current or prospective 

delegate agencies. 

7. Serve as the Approving Official to 

sign audit determination letters only 

where resolution does not involve a cost 

disallowance. 

8. Approve and issue termination and 

suspension actions resulting from 

monitoring review reports approved and 

issued by the Regional Office. 

(b) Limitations 

1. The approval of grant applications 

requires concurrence of the appropriate 

Grants Officer. 

2. The approval of contract proposals 

and awards are subject to the 

requirements of the Federal Acquisition 

Regulations and require consultation 

with the Director, Office of Head Start 

and the concurrence of the Contracting 

Officer. 

3. The approval and issuance of 

terminations and suspensions resulting 

from monitoring review reports 

approved and issued by the Regional 

Office require the concurrence of the 

Director, Office of Head Start. 

4. This redelegation shall be exercised 

under financial and administrative 

requirements applicable to all 

Administration for Children and 

Families authorities. 

5. Any redelegation shall be in writing 

and prompt notification must be 

provided to all affected managers, 

supervisors, and other personnel, and 

requires the concurrence of the Deputy 

Assistant Secretary for Administration. 

(c) Effective Date 

This redelegation was effective on 

April 26, 2007. 

(d) Effect on Existing Delegations 

This redelegation of authority 

supersedes all previous delegations 

from the Director, Office of Head Start, 

on these subjects. 

I hereby affirm and ratify any actions 

taken by the Director, Program 

Operations Division which, in effect, 

involved the exercise of these 

authorities prior to the effective date of 

this redelegation. 

Dated: May 15, 2007. 

Channell Wilkins, 

Director, Office of Head Start. 

[FR Doc. E7–9925 Filed 5–22–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Statement of Organization, Functions 

and Delegation of Authority 

Notice is hereby given that I have 

redelegated to the Regional Program 

Managers, American Indian Alaska 

Native Program Branch Chief, and 

Migrant and Seasonal Program Branch 

Chief, Office of Head Start, the 

following authorities vested in me by 

the Director, Office of Head Start, in the 

memoranda dated April 26, 2007. 

(a) Authorities Delegated 

1. Approve and disapprove refunding 

and supplemental funding applications 

for existing grantees, not including 

designated interim grantees. 

2. Approve and disapprove 

collaboration grant applications 

authorized under 42 U.S.C. 9835. 

3. Approve and disapprove contract 

proposals for award, not including 

proposals for national interim grantee 

contracts. 

4. Approve and disapprove quality 

improvement plans (QIP) as required 

under 42 U.S.C. 9836A(d)(2)(B). 

5. Conduct, as the responsible HHS 

official, informal meetings with current 

grantees or current or prospective 

delegate agencies as authorized by 45 

CFR 1303.11 and 1303.12. 

6. Conduct, as the responsible HHS 

official, informal meetings authorized 

by 45 CFR part 1303.21 related to 

appeals by current or prospective 

delegate agencies. 

7. Serve as the Approving Official to 

sign audit determination letters only 

where resolution does not involve a cost 

disallowance. 

8. Approve and issue termination and 

suspension actions resulting from 

monitoring review reports approved and 

issued by the Regional Office. 

(b) Limitations 

1. The approval of grant applications 

requires concurrence of the appropriate 

Grants Officer. 

2. The approval of contract proposals 

and awards are subject to the 

requirements of the Federal Acquisition 

Regulations and require consultation 

with the Director, Office of Head Start 

and the concurrence of the Contracting 

Officer. 

3. The approval and issuance of 

terminations and suspensions resulting 

from monitoring review reports 

approved and issued by the Regional 

Office require the concurrence of the 

Director, Office of Head Start. 

4. This redelegation shall be exercised 

under financial and administrative 

requirements applicable to all 

Administration for Children and 

Families authorities. 

5. Any redelegation shall be in writing 

and prompt notification must be 

provided to all affected managers, 

supervisors, and other personnel, and 

requires the concurrence of the Deputy 

Assistant Secretary for Administration. 

(c) Effective Date 

This redelegation was effective on 

April 26, 2007. 

(d) Effect on Existing Delegations 

This redelegation of authority 

supersedes all previous delegations 

from the Director, Office of Head Start, 

on these subjects. 

I hereby affirm and ratify any actions 

taken by any Regional Program 

Manager, the American Indian Alaska 

Native Program Branch Chief or the 

Migrant and Seasonal Program Branch 

Chief which, in effect, involved the 

exercise of these authorities prior to the 

effective date of this redelegation. 

Dated: May 14, 2007. 

Renee Perthuis, 

Director, Program Operations Division. 

[FR Doc. E7–9928 Filed 5–22–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006E–0260] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; ORENCIA 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) has determined 

the regulatory review period for 

ORENCIA and is publishing this notice 

of that determination as required by 

law. FDA has made the determination 

because of the submission of an 

application to the Director of Patents 

and Trademarks, Department of 

Commerce, for the extension of a patent 


pwalker on PROD1PC71 with NOTICES